26 December 2017 - Supports lead program, VAL-083, in on-going clinical trials.

DelMar Pharmaceuticals today announced that the U.S. FDA has granted fast track designation for the company's lead product candidate, VAL-083, in recurrent glioblastoma (rGBM).

This fast track status applies to two ongoing clinical trials sponsored by DelMar Pharmaceuticals to evaluate VAL-083 as a potential treatment for rGBM. These trials include:

• A Phase 2 study in bevacizumab-naïve MGMT-unmethylated GBM patients conducted in collaboration with The University of Texas MD Anderson Cancer Center; and
  
• A Phase 3 study of patients whose disease has progressed following prior treatment with temozolomide and bevacizumab (the STAR-3 trial).
  

Read DelMar Pharmaceuticals press release